Key result
Pharmacoinvasive strategy linked to ~73% lower 30-day major cardiovascular events vs thrombolysis alone in STEMI.
Why the study?
Pharmacoinvasive strategy is promising for STEMI management, but 30-day outcomes comparing thrombolysis alone versus thrombolysis followed by PCI in north India needed evaluation.
Does a pharmacoinvasive strategy reduce angina and dyspnea at 30 days compared to thrombolysis alone in STEMI patients?
Observational (n=657)
No
Does a pharmacoinvasive strategy reduce angina and dyspnea at 30 days compared to thrombolysis alone in STEMI patients?
A pharmacoinvasive strategy reduces 30-day symptoms of angina and dyspnea compared to thrombolysis alone in STEMI patients.
Answers are grounded in this paper and cite their sources.
Pharmacoinvasive strategy was associated with lower 30-day MACE in STEMI; hypothesis-generating for symptom relief, needs RCT confirmation.
STEMI is an event where transmural myocardial ischemia induces myocardial necrosis. PI strategy is a promising strategy in the management of STEMI. It is prospective registry study conducted in Cardiology Department, KGMU between January-June 2016 to know 30 day outcome of thrombolysis alone or thrombolysis followed by PCI in north India.At 30 day follow up, patients undergoing PI strategy,complained less of angina and dyspnea compared to thrombolysis arm.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2020) conducted an observational in ST-Elevation Myocardial Infarction (STEMI) (n=657). Pharmacoinvasive strategy (PI) vs. Thrombolysis alone was evaluated on Major adverse cardiovascular outcome (MACE) up to 30 days (OR 3.71, p=<0.001). A pharmacoinvasive strategy reduced 30-day major adverse cardiovascular events to 9.82% compared to 28.76% with thrombolysis alone in patients with STEMI.
Synapse has enriched 10 related papers. Consider them for comparative context: